Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bluejay Diagnostics, Inc. is a clinical diagnostics company focused on the development and commercialization of rapid, point-of-care tests for infectious and inflammatory diseases. The company operates within the in vitro diagnostics (IVD) and point-of-care testing segments of the healthcare industry, with an emphasis on delivering fast, accurate results in decentralized clinical settings. Its core value proposition centers on enabling clinicians to make timely treatment decisions without reliance on centralized laboratory infrastructure.
The company’s primary business activity is the development of its proprietary LumiraDx-based Symphony platform–independent diagnostic technology, most notably the Symphony IL-6 Test, which is designed to rapidly measure interleukin-6 (IL-6), a key biomarker associated with severe inflammation and sepsis. Bluejay Diagnostics, Inc. was founded in 2015 and later became publicly traded through an initial public offering in 2022. Since inception, the company has remained in a development-stage profile, focusing on regulatory clearance, clinical validation, and preparation for commercial launch rather than broad revenue generation.
Business Operations
Bluejay Diagnostics, Inc. operates primarily as a single-reportable-segment company centered on diagnostic test development and commercialization. Its business model is based on the sale of diagnostic testing instruments and single-use assay cartridges, with future revenue expected to be driven by recurring consumable sales once commercial adoption is achieved. As of the most recent public disclosures, the company has not reported material commercial revenue and continues to incur operating losses associated with research, development, and regulatory activities.
Operationally, the company’s activities include assay development, clinical studies, regulatory submissions, manufacturing scale-up through third-party partners, and early-stage commercialization planning. The company does not own large-scale manufacturing facilities and instead relies on outsourced manufacturing and supply chain partners. There are no disclosed joint ventures, and the company operates without significant subsidiary structures, maintaining a relatively streamlined corporate and operational footprint.
Strategic Position & Investments
The strategic focus of Bluejay Diagnostics, Inc. is to address unmet needs in acute care diagnostics by enabling rapid biomarker testing directly at the point of care. The Symphony IL-6 Test is positioned for use in hospital emergency departments, intensive care units, and other acute settings where rapid inflammation assessment may influence patient management. The company’s growth strategy is centered on obtaining regulatory authorization, expanding its assay menu beyond IL-6, and leveraging its core technology platform for additional inflammatory and infectious disease markers.
The company has historically invested the majority of its capital into research and development, clinical validation studies, and regulatory preparation. There is no public disclosure of completed material acquisitions, and investments have primarily been internal. Expansion into adjacent biomarkers and broader diagnostic panels is identified as a longer-term opportunity, though the timing and scope of such expansion remain dependent on regulatory outcomes and capital availability.
Geographic Footprint
Bluejay Diagnostics, Inc. is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operational focus is currently concentrated in North America, particularly the U.S. healthcare market, which represents its initial regulatory and commercialization target. Clinical development activities and regulatory submissions have been primarily aligned with U.S. regulatory standards.
While the company has indicated potential future interest in international markets, including Europe and other developed healthcare regions, it does not currently report material international operations or revenue. Any global expansion is expected to follow U.S. regulatory clearance and early commercial adoption, with international partnerships or distributors likely required to support broader geographic reach.
Leadership & Governance
Bluejay Diagnostics, Inc. is led by an executive team with experience in diagnostics, life sciences, and medical device commercialization. The leadership emphasizes disciplined clinical validation, regulatory compliance, and focused execution as the company transitions from development to potential commercialization. Governance is overseen by a board of directors with backgrounds in healthcare, finance, and biotechnology.
Key executives include:
- Joseph L. Hernandez – Chief Executive Officer and President
- Robert H. Martin – Chief Financial Officer
- Andrew J. Miller – Chief Operating Officer
- Eric J. Langlois – Chief Technology Officer
The leadership’s stated strategic vision centers on building a scalable point-of-care diagnostics platform while managing capital prudently and advancing products through regulatory milestones in a highly regulated industry.